New York, March 1, 2026, 15:18 (EST) — Markets are done for the day.
AbbVie Inc. wrapped up Friday’s session with a 3.3% gain, finishing at $232.08. After-hours, the stock edged down to $231.13. U.S. markets were closed on Sunday.
The stock broke higher even as the broader indexes stumbled—S&P 500 slipped 0.43%, Dow dropped 1.05%. AbbVie moved ahead of rival pharma names, and more shares changed hands than usual, suggesting buyers showed up after the stock’s three-day dip.
Traders already have their eyes on a handful of short-term triggers before the next session: insider trades logged post-close, a planned appearance from management, and a bond sale wrapping up this week. These won’t settle the ongoing debate around AbbVie’s growth story, but they’ve got enough weight to nudge the stock.
Executive vice president, general counsel and secretary Perry C. Siatis exercised stock options and sold off 22,381 shares at $230 apiece on Feb. 25, according to a Form 4. Siatis now holds 38,137 shares in his own name following the transaction. The Form 4, filed with the U.S. Securities and Exchange Commission, details insider trades.
AbbVie’s latest 8-K detailed plans for a senior notes sale, and investors have been picking through the deal. The company expects net proceeds of roughly $7.95 billion, with closing slated for March 4. That cash is set to go toward paying down a short-term loan, with the rest earmarked for general corporate needs and more debt repayment.
Looking ahead to Tuesday, AbbVie plans to have its management team participate in TD Cowen’s annual health care conference on March 3. They’re scheduled for a fireside chat at 10:10 a.m. Central Time, with a webcast accessible from the company’s investor website.
But the main issue remains with the products themselves. AbbVie has told investors to expect 2026 adjusted earnings between $14.37 and $14.57 a share, projecting Rinvoq and Skyrizi will bring in roughly $31.6 billion combined that year. CFO Scott Reents has pointed out “low-single-digit pricing headwinds.” William Blair’s Matt Phipps notes investors are uneasy about rising competition in immunology, with Johnson & Johnson’s Tremfya drawing particular attention. Reuters
Competition swings both directions for the stock. If management delivers straightforward remarks on demand and pricing, Friday’s rally could keep going. But investors don’t wait around—signs of share slippage, steeper rebates, or drag on new therapies? This name usually feels it right away.
When trading kicks off Monday, eyes will be on AbbVie to see if it keeps last week’s late surge going—especially as big pharma stocks have seen rapid rotation lately. Immediate focus turns to Tuesday, with the TD Cowen event, and then to Wednesday, when the notes sale is slated to settle.
